Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 5

1.

A randomized controlled trial assessing the effects of raltegravir intensification on endothelial function in treated HIV infection.

Hatano H, Scherzer R, Wu Y, Harvill K, Maka K, Hoh R, Sinclair E, Palmer S, Martin JN, Busch MP, Deeks SG, Hsue PY.

J Acquir Immune Defic Syndr. 2012 Nov 1;61(3):317-25. doi: 10.1097/QAI.0b013e31826e7d0f.

2.

Raltegravir: in treatment-naive patients with HIV-1 infection.

Croxtall JD, Scott LJ.

Drugs. 2010 Mar 26;70(5):631-42. doi: 10.2165/11204590-000000000-00000. Review.

PMID:
20329808
3.

Raltegravir: a review of its use in the management of HIV-1 infection in children and adolescents.

Perry CM.

Paediatr Drugs. 2014 Feb;16(1):91-100. doi: 10.1007/s40272-013-0058-9. Review.

PMID:
24277175
4.

[Raltegravir is the first HIV integrase inhibitor as part of antiretroviral treatment regimens].

Kravchenko AV.

Ter Arkh. 2010;82(11):27-32. Review. Russian.

PMID:
21381345
5.

The use of HIV-1 integrase inhibitors in antiretroviral naive patients.

Lennox JL.

Curr Opin HIV AIDS. 2012 Sep;7(5):409-14. doi: 10.1097/COH.0b013e3283562a27. Review.

PMID:
22789985

Supplemental Content

Support Center